Explainer-Why the US is negotiating the price of 10 drugs
By Patrick Wingrove
(Reuters) — The U.S. government on Tuesday released a list of 10 prescription medicines that will be subject to the first-ever price negotiations by the Medicare health program that covers Americans aged 65 and over.
These include Merck & Co's diabetes drug Januvia, big-selling blood thinner Eliquis from Bristol Myers (NYSE:BMY) Squibb and Pfizer (NYSE:PFE), and AbbVie (NYSE:ABBV)'s leukemia treatment Imbruvica.
Here is what you need to know about the negotiation process and possible role in lowering drug costs.
What are the Medicare drug price negotiations?
Under President Joe Biden’s Inflation Reduction Act, which was passed into law last year, the government will negotiate with drugmakers the prices of a select number of medicines on which it spends the most annually for the Medicare health program that covers 66 million Americans.
The Medicare agency, known as the Centers for Medicare & Medicaid Services (CMS), was previously forbidden by law from bartering prices with manufacturers. Given that power now, it aims to save $25 billion per year on drug costs by 2031.
After spending the past year getting input from drugmakers and members of the public and putting together rules for the program, the negotiations kick off with Tuesday’s announcement.
Prices settled on for these first 10 drugs will not go into effect until 2026, and several drugmakers and business groups have filed lawsuits seeking to derail the entire process.
What happens next?
Drugmakers have until Oct. 1 to agree to the negotiations. If they refuse, they face heavy fines. By Oct. 2, they must hand over extensive data the government requires to come up with its proposed lower prices.
Medicare plans to send its first offers to
Read more on investing.com
